246 results on '"Windyga J"'
Search Results
2. OC 14.1 Phase 3 Prospective, Randomized, Controlled, Open-Label, Multicenter, Crossover Study of Recombinant ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura
3. OC 59.1 Concizumab Prophylaxis in Patients with Haemophilia A or B without Inhibitors: Efficacy and Safety Results from the Primary Analysis of the Phase 3 Explorer8 Study
4. OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study
5. OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study
6. PB1229 Haemostatic Control with Recombinant Porcine Factor VIII in Acquired Haemophilia A
7. PB1282 Real-World Unmet Needs of Adult Patients with Severe Hemophilia A without Inhibitors in Poland: How to Select the Optimal Therapy?
8. Pain relief with Eptacog beta in haemophilia patients with inhibitors
9. Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study
10. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
11. Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey
12. PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
13. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series
14. Outcome measures in European patients with haemophilia: Survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB
15. Safety and efficacy of BAY 81–8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme
16. SAFETY AND EFFECTIVENESS OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) MONOTHERAPY IN PATIENTS WITH HEMOPHILIA AND INHIBITORS (PWHI) UNDERGOING SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
17. Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey
18. Determinants of inhibitor development in previously treated hemophilia A patients: OR144
19. Safety, efficacy and pharmacokinetics of a recombinant von willebrand factor in patients with severe von willebrand disease: a prospective clinical trial: OR088
20. SAFETY AND EFFECTIVENESS OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) MONOTHERAPY IN PATIENTS WITH HEMOPHILIA AND INHIBITORS (PWHI) UNDERGOING SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
21. Overall Health, Daily Functioning, and Quality of Life in Acute Hepatic Porphyria Patients: ENVISION, a Phase 3 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
22. Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders
23. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
24. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report
25. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in previously treated patients with severe haemophilia A
26. An Analysis of Healthcare Utilization and Costs Associated with Patients with Acute Hepatic Porphyrias (AHPS) with Recurrent Attacks in Explore: A Prospective, Multinational Natural History Study of Patients with AHP
27. Fifth Åland Island conference on von Willebrand disease
28. Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria
29. EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria with recurrent attacks
30. Impact of acute hepatic porphyrias on quality of life and work loss: An analysis of EXPLORE natural history study
31. [PP.29.14] SYMPATHETIC ACTIVITY IS DECREASED IN PATIENTS WITH POLYCYTHEMIA VERA AS COMPARED WITH PATIENTS WITH ESSENTIAL HYPERTENSION
32. PK-guided personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in adults with severe haemophilia A
33. Inhibitor development in non-severe haemophilia across Europe
34. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series
35. T-13-01: Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study.
36. [PP.12.17] EVALUATION OF SELECTED PARAMETERS OF NEURO-HORMONAL ACTIVITY AND RETINAL AND INTRARENAL PERFUSION IN PATIENTS WITH POLYCYTHEMIA VERA
37. Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors
38. PHS39 - An Analysis of Healthcare Utilization and Costs Associated with Patients with Acute Hepatic Porphyrias (AHPS) with Recurrent Attacks in Explore: A Prospective, Multinational Natural History Study of Patients with AHP
39. SAT-041 - Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria
40. SAT-040 - Impact of acute hepatic porphyrias on quality of life and work loss: An analysis of EXPLORE natural history study
41. PS-143 - EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria with recurrent attacks
42. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.
43. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease
44. Operacje wymiany stawów u chorych na hemofilię powikłaną inhibitorem – doświadczenia własne
45. Rodzinne występowanie udaru niedokrwiennego i ostrego zespołu wieńcowego STEMI u mężczyzny z homozygotycznym polimorfizmem C677T MTHFR i łagodną hiperhomocysteinemią
46. Częstość występowania mutacji inwersyjnych w intronie 22 (INV22) i w intronie 1 (INV1) genu F8 u polskich chorych na ciężką hemofilię A
47. The Acquired Deficiency of Factors II, VII, IX, and X in the Course of the Intoxication of Second Generation Anticoagulant Rodenticides in Female Patient Suffering from Severe Diathesis Haemorrhagica – a case report
48. Wstępna ocena zastosowania dapsonu u chorych z przewlekłą oporną pierwotną małopłytkowością immunologiczną (ITP)
49. Course of pregnancy and labor and perioperative management of two patients with Bernard-Soulier syndrome – case report and literature review
50. Acquired Hemophilia in Patient with Chronic Myelomonocytic Leukemia (CMML1) – a case report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.